Immune checkpoint antibody development focuses on modulating immune responses for cancer therapy. These antibodies target checkpoint molecules like PD-1, CTLA-4, and LAG-3, helping to enhance T-cell activation and boost antitumor immunity. Advanced techniques, including monoclonal antibody engineering and fragment-based development, improve specificity and therapeutic efficacy. By optimizing immune checkpoint antibodies, researchers aim to create next-generation immunotherapies with greater precision and long-lasting effects.